Clinical Trial Update: Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fasting Conditions [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 bioequivalence study evaluating metoprolol succinate extended-release tablets 200 mg under fasting conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris
• Heart Failure
• Hypertension

Drugs mentioned

• Metoprolol succinate extended-release tablets 200 mg (metoprolol succinate)

Snippet

Sponsor: IPCA Laboratories Ltd. | Conditions: Fasting | Phase 1 | Status: COMPLETED